Cedric Francois
CIK 1658080 · Chief Executive Officer · last filed 2026-05-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$0
Companies
1
Total Filings
90
Lifetime Open-Market Net
-$50.23M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | Chief Executive Officer | 195,952 | $41.03 | $8.04M | -$50.23M | 70 | 2026-05-14 |
Recent Filings · Page 5 of 9
90 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-09-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −150,000 | -$6.26M | EDGAR |
| 2023-09-01 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +150,000 | -$5.46M | EDGAR |
| 2023-05-25 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Gift (G) | — | $0 | EDGAR |
| 2023-05-18 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +20,000 | -$2.44M | EDGAR |
| 2023-05-16 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −30,000 | -$2.64M | EDGAR |
| 2023-04-28 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Gift (G) | — | $0 | EDGAR |
| 2023-04-20 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +20,000 | -$2.33M | EDGAR |
| 2023-04-18 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Notice (144) | −30,000 | -$2.48M | EDGAR |
| 2023-04-05 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Gift (G) | — | $0 | EDGAR |
| 2023-03-23 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +127,221 | -$1.27M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.